TUMOURPRINT SIGNED
High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0TUMOURPRINT project word cloud
Explore the words cloud of the TUMOURPRINT project. It provides you a very rough idea of what is the project "TUMOURPRINT" about.
Project "TUMOURPRINT" data sheet
The following table provides information about the project.
| Coordinator |
CELLINK AB
Organization address contact info |
| Coordinator Country | Sweden [SE] |
| Project website | https://cellink.com/global/ |
| Total cost | 3˙500˙467 € |
| EC max contribution | 2˙450˙327 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-09-01 to 2021-01-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CELLINK AB | SE (GOTEBORG) | coordinator | 2˙450˙327.00 |
Map
Project objective
CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development).
The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.
Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-to-pay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way.
CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cell-specific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.
Deliverables
| Cancer cell lines selected | Documents, reports | 2019-11-28 17:30:38 |
| 10 hired employees | Demonstrators, pilots, prototypes | 2019-11-28 17:30:39 |
Take a look to the deliverables list in detail: detailed list of TUMOURPRINT deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUMOURPRINT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TUMOURPRINT" are provided by the European Opendata Portal: CORDIS opendata.